. 2021 Jan 21;16:19. doi: 10.1186/s13014-021-01745-1

Table 3.

The proportion of sampled cases that are considered cost-effective at different thresholds and varying cost of proton therapy for the whole patient cohort (for the patient where proton therapy is least likely to be cost-effective on the left-hand side of the parentheses, and most likely to be cost-effective on the right-hand side)

Cost-effectiveness threshold	Proton therapy cost
$100,000/QALY	27.5% (21.3, 44.9%)	32.6% (22.7, 51.3%)	36.4% (24.0, 54.7%)	56.0% (34.6, 66.8%)
$250,000/QALY	35.2% (23.4, 53.0%)	39.4% (24.2, 56.2%)	47.0% (26.3, 61.4%)	65.7% (51.8, 70.8%)
$500,000/QALY	43.2% (24.7, 58.6%)	48.4% (27.2, 62.3%)	56.5% (34.7, 67.1%)	70.5% (61.8, 72.5%)

Cost-effectiveness threshold

Proton therapy cost

Base case: $36,659

$31,659

$26,659

$21,659

$100,000/QALY

27.5%

(21.3, 44.9%)

32.6%

(22.7, 51.3%)

36.4%

(24.0, 54.7%)

56.0%

(34.6, 66.8%)

$250,000/QALY

35.2%

(23.4, 53.0%)

39.4%

(24.2, 56.2%)

47.0%

(26.3, 61.4%)

65.7%

(51.8, 70.8%)

$500,000/QALY

43.2%

(24.7, 58.6%)

48.4%

(27.2, 62.3%)

56.5%

(34.7, 67.1%)

70.5%

(61.8, 72.5%)